IN2014CN02680A - - Google Patents

Info

Publication number
IN2014CN02680A
IN2014CN02680A IN2680CHN2014A IN2014CN02680A IN 2014CN02680 A IN2014CN02680 A IN 2014CN02680A IN 2680CHN2014 A IN2680CHN2014 A IN 2680CHN2014A IN 2014CN02680 A IN2014CN02680 A IN 2014CN02680A
Authority
IN
India
Prior art keywords
membered
1compound
mixtures
indicates
preventing
Prior art date
Application number
Inventor
Yoram Kapulnik
Hinanit Koltai
Ronit Yarden
Cristina Prandi
Original Assignee
Israel State
Univ Georgetown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Israel State, Univ Georgetown filed Critical Israel State
Publication of IN2014CN02680A publication Critical patent/IN2014CN02680A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

1Compound of formula X wherein P is a fused ring system comprising one 6 membered and two 5 membered rings; v indicates an S or R configuration; or individual isomers or pharmaceutically acceptable salts thereof or mixtures thereof in the preparation of an active agent for preventing or inhibiting cell proliferation or for inducing cell death.
IN2680CHN2014 2011-09-21 2012-09-20 IN2014CN02680A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161537062P 2011-09-21 2011-09-21
US201261614965P 2012-03-23 2012-03-23
PCT/IL2012/050381 WO2013042124A1 (en) 2011-09-21 2012-09-20 Use of strigolactones and strigolactone analogs for treating proliferative conditions

Publications (1)

Publication Number Publication Date
IN2014CN02680A true IN2014CN02680A (en) 2015-07-03

Family

ID=47913975

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2680CHN2014 IN2014CN02680A (en) 2011-09-21 2012-09-20

Country Status (7)

Country Link
US (1) US10208007B2 (en)
EP (1) EP2758392B1 (en)
JP (1) JP2014527979A (en)
CN (1) CN104053655A (en)
CA (1) CA2849343C (en)
IN (1) IN2014CN02680A (en)
WO (1) WO2013042124A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3041479B1 (en) 2013-09-06 2023-04-26 Vanda Pharmaceuticals Inc. Treatment of cyr61- and vegf-mediated conditions
US20180235213A1 (en) * 2015-05-14 2018-08-23 The State of Israel Ministry of Agriculture & Rural Develop. Agricultural Research Organization Plant hormone application
GB201615544D0 (en) * 2016-09-13 2016-10-26 Syngenta Participations Ag Plant Growth regulator compounds
CN108558796B (en) * 2018-05-07 2020-04-07 南开大学 Hydroxy methylene hydrindone derivatives, preparation method and application thereof
CN108675974B (en) * 2018-05-07 2020-04-07 南开大学 Strigolactone derivatives and preparation method and application thereof
WO2020095260A1 (en) * 2018-11-08 2020-05-14 Universita' Degli Studi Di Torino Strigolactones for use in preventing and/or treating infections caused by viruses of the herpesviridae family

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865897B1 (en) * 2004-02-10 2006-06-09 Univ Toulouse MODULATORS FOR THE DEVELOPMENT OF MYCORRHIZIAN FUNGI WITH ARBUSCLES, AND.
TW200904330A (en) 2007-06-15 2009-02-01 Bayer Cropscience Sa Pesticidal composition comprising a strigolactone derivative and a fungicide compound
TW200904331A (en) 2007-06-15 2009-02-01 Bayer Cropscience Sa Pesticidal composition comprising a strigolactone derivative and an insecticide compound
EP2248421A1 (en) 2009-05-07 2010-11-10 GMI - Gregor-Mendel-Institut für Molekulare Pflanzenbiologie GmbH Accumulation of biomass in plants
FI20106119A0 (en) 2010-10-27 2010-10-27 Sirtuin Valley Oy A composition for influencing energy metabolism

Also Published As

Publication number Publication date
WO2013042124A8 (en) 2013-07-25
CN104053655A (en) 2014-09-17
EP2758392A1 (en) 2014-07-30
EP2758392B1 (en) 2019-09-18
US20140323563A1 (en) 2014-10-30
JP2014527979A (en) 2014-10-23
EP2758392A4 (en) 2015-05-20
CA2849343A1 (en) 2013-03-28
CA2849343C (en) 2020-12-15
WO2013042124A1 (en) 2013-03-28
US10208007B2 (en) 2019-02-19

Similar Documents

Publication Publication Date Title
UY39630A (en) BROMODOMAIN INHIBITORS
MY196383A (en) Benzo[B]Thiophene Compounds As Sting Agonists
IN2014CN02680A (en)
MX345928B (en) Therapeutically active compositions and their methods of use.
PH12016500024A1 (en) Bromodomain inhibitor
TN2015000002A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
SA515360469B1 (en) Heterocyclic compounds for inhibiting glutaminase and their methods of use
CR20140567A (en) FORMULATIONS AND METHODS FOR THE VAGINAL ADMINISTRATION OF ANTIPROGESTINES
MY197785A (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
MX2012013945A (en) New forms of rifaximin and uses thereof.
DOP2014000081A (en) COMPOUNDS AND PROCEDURES TO IMPROVE INNATE IMMUNE RESPONSES
IN2014DN06869A (en)
TW201613864A (en) Novel compounds
MY173564A (en) Cxcr7 receptor modulators
WO2014153495A9 (en) Novel stat3 inhibitors
MX2015007940A (en) Tricyclic compounds as cftr inhibitors.
MX2015005762A (en) Co-micronisation product comprising ulipristal acetate.
ECSP14013155A (en) 1-PIPERAZINO-3-PHENYL-INDANOS DEUTERATED FOR THE TREATMENT OF SCHIZOPHRENIA
WO2014062838A3 (en) Pkm2 modulators and methods for their use
MX2014013664A (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexy l) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide.
MX2014015345A (en) Pyranopyridone inhibitors of tankyrase.
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
MX2014005960A (en) Nitrogen-containing fused ring compounds for use as crth2 antagonists.
TN2014000484A1 (en) Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis.
CU20100087A7 (en) SOME DERIVATIVES OF 2-PIRAZINONA AND ITS USE AS INHIBITORS OF ELASTASA DE LOS NEUTRÓFILOS